Sign up to save your podcasts
Or
Share MBCC: HER2-Positive Breast Cancer Demonstrates Heterogenous Outcomes
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
MBCC: HER2-Positive Breast Cancer Demonstrates Heterogenous Outcomes
The discovery of human epidermal growth factor receptor 2 (HER2)-positive breast cancer subtypes is not yet complete, according to Mark D. Pegram, MD, who will be delivering a presentation on the different clinical outcomes of these subtypes at the Miami Breast Cancer Conference this week.
View all episodes
By Cancer NetworkThe discovery of human epidermal growth factor receptor 2 (HER2)-positive breast cancer subtypes is not yet complete, according to Mark D. Pegram, MD, who will be delivering a presentation on the different clinical outcomes of these subtypes at the Miami Breast Cancer Conference this week.